These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 736036)

  • 1. Demonstration of a platelet bypass mechanism in the clotting system using an acquired anticoagulant.
    Firkin BG; Booth P; Hendrix L; Howard MA
    Am J Hematol; 1978; 5(2):81-92. PubMed ID: 736036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulants.
    Galli M; Béguin S; Lindhout T; Hemker CH
    Br J Haematol; 1989 Aug; 72(4):549-55. PubMed ID: 2505834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigations of the lupus-like inhibitor by-passing activity of platelets.
    Howard MA; Firkin BG
    Thromb Haemost; 1983 Dec; 50(4):775-9. PubMed ID: 6420922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic defect due to acquired circulating inhibitors against lipid procoagulant and factor VIII.
    Pechet L; Snyder LM; Chesney C; Colman RW
    Thromb Diath Haemorrh; 1974 Sep; 32(1):90-104. PubMed ID: 4548947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns.
    Exner T; Rickard KA; Kronenberg H
    Br J Haematol; 1978 Sep; 40(1):143-51. PubMed ID: 568479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating anticoagulant against factor XI and thrombocytopenia with platelet aggregation inhibition in systemic lupus erythematosus.
    Leone G; Accorra F; Boni P
    Acta Haematol; 1977; 58(4):240-5. PubMed ID: 410226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
    Al-Mondhiry H; Galanakis D
    J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus.
    Davis S; Furie BC; Griffin JH; Furie B; Willey R
    Am J Hematol; 1978; 4(4):401-7. PubMed ID: 717399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two simple tests for the lupus anticoagulant.
    Exner T
    Am J Clin Pathol; 1985 Feb; 83(2):215-8. PubMed ID: 3918436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on phospholipids in the action of a lupus coagulation inhibitor.
    Exner T; Rickard KA; Kronenberg H
    Pathology; 1975 Oct; 7(4):319-28. PubMed ID: 1223721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet function and coagulation profile in lupus erythematosus. Studies in 50 patients.
    Regan MG; Lackner H; Karpatkin S
    Ann Intern Med; 1974 Oct; 81(4):462-8. PubMed ID: 4213298
    [No Abstract]   [Full Text] [Related]  

  • 12. Assays for lupus anticoagulant: the sensitivity of different assays.
    Jain A; Dash S; Marwaha N; Deodhar SD; Sehgal S
    Med Lab Sci; 1991 Jan; 48(1):31-5. PubMed ID: 1905773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of procoagulant phospholipid interfering in tests for lupus anticoagulant.
    Exner T; Low J
    Thromb Res; 2004; 114(5-6):547-52. PubMed ID: 15507290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivities of antiphospholipid antibodies to blood cells and their effects on platelet aggregations in vitro.
    Ichikawa Y; Kobayashi N; Kawada T; Shimizu H; Moriuchi J; Ono H; Watanabe K; Arimori S
    Clin Exp Rheumatol; 1990; 8(5):461-8. PubMed ID: 2124528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar mechanism of various lupus anticoagulants.
    Exner T
    Thromb Haemost; 1985 Feb; 53(1):15-8. PubMed ID: 3922078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus--possible association with thrombotic and thrombocytopenic complications.
    Nojima J; Suehisa E; Kuratsune H; Machii T; Koike T; Kitani T; Kanakura Y; Amino N
    Thromb Haemost; 1999 Mar; 81(3):436-41. PubMed ID: 10102474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Circulating lupus-type anticoagulant, a risk factor for thrombosis by inhibition of protein C activation].
    Cariou R; Tobelem G; Caen J
    C R Acad Sci III; 1986; 303(4):113-8. PubMed ID: 3019490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The induction of an acquired storage pool deficiency of the thrombocytes by IgG antibodies in systemic lupus erythematosus and chronic polyarthritis].
    Falke S; Avenarius HJ; Deicher H
    Z Rheumatol; 1990; 49(2):70-6. PubMed ID: 2349839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin generation assay as a possible tool for assessment of reduced activity of clotting factors induced by antiphospholipid antibodies and in-vitro evaluation of treatment options.
    Livnat T; Zivelin A; Tamarin I; Guetta V; Salomon O
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):661-6. PubMed ID: 19730246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of platelet prothrombinase activity by a lupus anticoagulant.
    Dahlbäck B; Nilsson IM; Frohm B
    Blood; 1983 Jul; 62(1):218-25. PubMed ID: 6407549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.